China National Biotec Group announced a research collaboration with Riboxx Pharmaceuticals GmbH, a German biopharma. The two companies will evaluate the combination of Riboxxim®, which is a TLR3 agonist from Riboxx, and a CNBG antigen as a treatment for an infectious disease. Riboxx characterized the disease as one of the world’s deadliest, but did not name it. Riboxxim is an immune system modulator. More details.... Share this with colleagues: // //